We are live on ! Find out more
LEXX icon

Lexaria Bioscience
LEXX

15 hedge funds and large institutions have $1.77M invested in Lexaria Bioscience in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

172% more capital invested

Capital invested by funds: $651K → $1.77M (+$1.12M)

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

10.86% more ownership

Funds ownership: 11.03% → 21.9% (+11%)

7% more funds holding

Funds holding: 14 → 15 (+1)

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

Holders
15
Holders Change
+1
Holders Change %
+7.14%
% of All Funds
0.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
4
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$812K
2
TSS
Two Sigma Securities
New York
+$9.63K
3
Renaissance Technologies
Renaissance Technologies
New York
+$2.01K
4
Wells Fargo
Wells Fargo
California
+$14
5
GCM
Gables Capital Management
Florida
+$12

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$11.2K
2
TRCT
Tower Research Capital (TRC)
New York
-$2.39K
3
ICM
Invenomic Capital Management
Massachusetts
-$2.05K
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$1.3K
5
Osaic Holdings
Osaic Holdings
Arizona
-$1.27K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$889K +$812K +889,272 New
ICM
2
Invenomic Capital Management
Massachusetts
$764K -$2.05K -2,241 -0.3%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$47K -$1.3K -1,421 -3%
Vanguard Group
4
Vanguard Group
Pennsylvania
$33.3K – – –
Renaissance Technologies
5
Renaissance Technologies
New York
$13K +$2.01K +2,200 +21%
TSS
6
Two Sigma Securities
New York
$10.5K +$9.63K +10,545 New
TRCT
7
Tower Research Capital (TRC)
New York
$8.33K -$2.39K -2,621 -24%
1832 Asset Management
8
1832 Asset Management
Ontario, Canada
$2.69K – – –
Wells Fargo
9
Wells Fargo
California
$1.09K +$14 +15 +1%
Osaic Holdings
10
Osaic Holdings
Arizona
$649 -$1.27K -1,393 -68%
APC
11
Aspire Private Capital
North Carolina
$399 – – –
FFA
12
Farther Finance Advisors
California
$166 – – –
Toronto Dominion Bank
13
Toronto Dominion Bank
Ontario, Canada
$13 – – –
GCM
14
Gables Capital Management
Florida
$13 +$12 +13 New
Susquehanna International Group
15
Susquehanna International Group
Pennsylvania
– -$11.2K -15,426 Closed
UBS Group
16
UBS Group
Switzerland
– -$72 -99 Closed

LEXX Hedge Fund Activity: Q3 2023 in Review

15 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience (LEXX) for Q3 2023, worth a combined $1.77M — up 172% from $651K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new LEXX positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 4 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $812K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $11.2K sold.

  • 15 institutional investors held Lexaria Bioscience (LEXX) as of Q3 2023, up from 14 in Q2 2023.
  • Funds reported $1.77M of Lexaria Bioscience stock for Q3 2023, up 172% quarter-over-quarter.
  • 3 funds opened new Lexaria Bioscience positions in Q3 2023 and 2 closed out, a net change of +1 holder.
  • The largest Lexaria Bioscience buyer in Q3 2023 was Armistice Capital, an estimated $812K added.
  • The largest Lexaria Bioscience seller in Q3 2023 was Susquehanna International Group, an estimated $11.2K sold.

Based on aggregated 13F filings for Q3 2023.